Zepzelca’s pivotal surprise
Jazz's somewhat low-key SCLC drug scores its biggest win yet.
Roche expands in KRAS
GDC-7035 enters the clinic, as does another bispecific against PD-L1 and VEGF.
Gritstone has a mountain to climb with Granite
The group is persevering with Granite, but funds might be hard to come by.
Regor’s selective approach attracts Roche
For $850m up front Roche gets to challenge Pfizer.
